New York greenlights a groundbreaking clinical trial of a THC-based oral solution, VER-01, targeting chronic sciatica pain—a move with national medical cannabis implications.

The FDA outlines its ibogaine trial vision, Compass Pathways reveals pricing and slow rollout plans, and early healthcare leaders weigh in—here’s what DMV readers need to know.

An evidence-based examination of THC delivery methods, CBD dosing protocols, therapeutic mechanisms, and legal frameworks across DC and Virginia.

EasyDay Edibles partners with Paradigm Partners and Brands to launch a multi-patented, battery-free cannabis inhaler in Washington, D.C.

Some states are moving to block or overturn marijuana ballot measures, shifting power over cannabis laws away from the public and into lawmakers’ hands.

As federal delays reshape cannabis financing, operators find resilience in beverage growth and restructuring strategies.

Florida state regulators cite Trulieve over illegal wastewater discharge at its Monticello cultivation facility, prompting environmental compliance mandates.

On Ben & Jerry’s The Mix podcast, the WNBA star urged nationwide legalization, citing jobs, state revenue and a safer alternative to painkillers—raising big questions for the DMV.

Georgia, Vermont and California officials say DEA has offered little implementation guidance after marijuana moved to Schedule III for state medical programs, leaving labeling, taxes and inspections unclear.

A Bay Area nonprofit is building an IRB-backed study of intramuscular ketamine-assisted psychotherapy for postpartum depression, with breastfeeding and access front and center.

The French Orange rolling paper booklet is now a 15-inch crossbody by RugSoda and Zig-Zag—bridging hip-hop history, fan demand and modern cannabis lifestyle.

A documented increase in medical cannabis authorizers and broad clinician support could reshape patient access and operator strategy. Here’s how DMV readers can think about it.

Anti-marijuana groups and a pharma company asked a D.C. appeals court to revive their challenge to a Medicare initiative that lets providers furnish certain hemp-derived CBD products to beneficiaries.

New Mexico’s Enforcement Bureau is actively investigating more than two dozen cannabis and hemp cases, including an alleged unlicensed mega-grow and unsafe hemp THC products.

A New Jersey lawsuit alleges a powerful state senator and partners used paper owners to capture social equity perks. Here’s what it means for cannabis culture—and the DMV.

Oregon pauses a proposed psilocybin fee increase, California earmarks $4.7M for psychedelic research, and the DEA moves to schedule five tryptamines—here’s why it matters.

Missouri is set to issue about 77 marijuana microbusiness licenses after a September drawings round. Here’s how new owners can avoid predatory contracts—and what DMV founders and investors can learn.

A living legend reflects on federal court, landrace genetics, the vanishing “true skunk,” and how cannabis contests should evolve — and why it matters in the DMV.

High Times spotlights how Grown Rogue carried an Oregon-grown cultivation approach into New Jersey—here’s why that matters for East Coast markets and DMV readers.

A Texas case profiled by High Times shows how extreme cannabis penalties still happen. Here’s what DMV readers should consider about risk, compliance and delivery rules.